Cancer Research

Avacta announces Phase I Clinical Trial Authorisation (CTA) for AVA6000

18 February 2021

Avacta, the developer of Affimer biotherapeutics and reagents, has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) for its Clinical Trial Authorisation (CTA) in the UK for a Phase I study of its lead pre|CISION pro-drug, AVA6000 pro-doxorubicin. In AVA6000, doxorubicin has been modified with Avacta’s pre|CISION chemistry, which renders the modified […]

Samsung Biologics obtains cancer immunotherapy IND approval from FDA

12 February 2021

Samsung Biologics has obtained Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy. In late 2018, National OncoVenture (NOV), a government-funded virtual oncology drug development program in Korea, approached Samsung Biologics for the development of EU101(NOV1801), an anti-4-1BB therapeutic monoclonal antibody provided by Eutilex (KOSDAQ:263050). […]

4D pharma collaboration with Merck and Pfizer for urothelial carcinoma

8 February 2021

4D pharma, a pharmaceutical company looking at the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, has announced a clinical trial collaboration and supply agreement with Merck and Pfizer for BAVENCIO(R) (avelumab), the immunotherapy approved as a first-line maintenance treatment for patients with locally advanced or metastatic urothelial […]

X-Chem and Genentech enter oncology discovery research collaboration

5 February 2021

X-Chem, expert in DNA-Encoded Library (DEL) technology to identify novel drug leads, has entered into a research collaboration and license agreement with Genentech, a member of the Roche Group. The goal of the collaboration is to discover and develop novel small molecule treatments in oncology. Under the terms of the agreement, X-Chem will deploy its […]

UCL and AstraZeneca collaborate on immuno-oncology research

4 February 2021

Researchers from UCL Division of Infection & Immunity will lead on two collaborative projects with AstraZeneca. The projects’ long-term aim is to contribute to the development of new cancer treatments. These research collaborations will investigate immune checkpoints which are key biochemical pathways that regulate our body’s immune responses. These are important in a number of […]

Taconic Biosciences expands immuno-oncology animal model portfolio

28 January 2021

Taconic Biosciences, global provider of drug discovery animal model solutions, has expanded its immuno-oncology portfolio. Immuno-oncology is a leading research priority because it uses the body’s own immune system to effectively treat some types of cancer. Syngeneic tumour animal models play a critical role because they use standard inbred mice that have a competent immune […]

Genetic changes in tumours could help predict if patients will respond to immunotherapy

27 January 2021

Researchers at the Francis Crick Institute, the UCL Cancer Institute, and the Cancer Research UK Lung Cancer Centre of Excellence have identified genetic changes in tumours which could be used to predict if immunotherapy drugs would be effective in individual patients. Immunotherapies have led to huge progress treating certain types of cancer, but only a […]

The importance of partnership and innovation in oncology

22 January 2021

Fostering synergies to accelerate innovation in oncology and make it attractive for partners has been the MATWIN motto for over a decade, writes CEO Lucia Robert, MATWIN who outlines the organisations’s work MATWIN is a French open-innovation platform dedicated to supporting innovation in oncology. For more than ten years, its goal has been to help […]

Syngeneic mouse models for preclinical immuno-oncology

19 January 2021

The advent of immuno-oncology has necessitated changes in the types of animal models used in oncology drug discovery. Syngeneic models — inbred mice bearing an engrafted tumour derived from a genetically identical mouse strain — are invaluable preclinical research tools that enable tumour studies in the context of a complete and functional immune system. These […]

How hard-to-treat cancers may benefit from new drug that targets pathways

18 January 2021

After decades of no luck, scientists have finally found a way to target the KRAS mutation – a common mutation found in several hard-to-treat cancers – according to a new study funded by Cancer Research UK and Wellcome. By targeting two components of the KRAS signalling pathway, a new drug was much better at stopping the growth […]

Next »

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free